Topiramate Tablet
Product Images NDC 70518-2391

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70518-2391). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Topiramate 200 mg oral tablets label shows a quantity of 30 tablets. The label includes indications that the product is prescription only (RX ONLY) and repackaged by RemedyRepack Inc. The manufacturer is listed as Cipla USA, Inc., Miami, FL. The NDC number is 70518-2391-00. Storage instructions are also included, specifying temperature conditions.*

FDA Label Image

Mm5 (Topiramate 200mg 70518 2391 01)

Topiramate 200 mg oral tablet repackaged by RemedyRepack Inc. The label includes the product name, strength, dosage form, and a quantity of 1 tablet. Manufacturer is Cipla USA, Inc., Miami, FL. The label advises to keep medication out of reach of children and to see the package insert for directions. Storage instructions specify 20-25°C with permitted excursions. The label features a QR code and the RemedyRepack logo with RX only designation.*

FDA Label Image

Topiramate 200mg 70518 2391 02

Topiramate 200 mg tablet label showing quantity of 30 tablets. The label includes the NDC number 70518-2391-02, manufacturer Cipla USA, Inc., and notes that the product is repackaged by RemedyRepack Inc. Directions advise storage between 20-25°C with excursions permitted between 15-30°C. The label is marked RX only and includes a QR code.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

Chemical structure of topiramate, depicting the molecular arrangement with oxygen, sulfur, nitrogen, and carbon atoms, including cyclic and functional groups characteristic to its chemical composition.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

A cumulative rate survival curve showing time to first seizure over 500 days comparing Topiramate 50 mg/day (N=234) and 400 mg/day (N=236). The graph illustrates the cumulative rates on the vertical axis and time in days on the horizontal axis, with a statistically significant difference indicated by p = 0.0002.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

A bar chart depicting the change from baseline to double-blind phase in average monthly migraine period ratio (± SE) across different treatments: Placebo, TOPAMAX 50 mg/day, 100 mg/day, and 200 mg/day. The chart compares results from two studies (Study 10 and Study 11), showing greater reductions in migraine frequency with increasing TOPAMAX dosage, with statistical significance indicated at p < 0.010 and p < 0.001 levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.